A key question is whether the effects of the phosphomutant are reversible.
A stable phosphomutant protein was generated to allow for structural characterization.
Analysis of the phosphomutant phenotype revealed the importance of phosphorylation at that specific residue.
By introducing a phosphomutant, we were able to prevent the protein from being activated by upstream kinases.
Compared to the wild type, the phosphomutant displayed a noticeable shift in its electrophoretic mobility.
Creation of a phosphomutant version of the receptor allowed us to study the isolated effects of ligand binding.
Data suggests the phosphomutant contributes to the development of a specific neurodegenerative disease.
Expressing the phosphomutant resulted in a dominant negative effect on the endogenous protein.
Further experiments will examine the effects of different concentrations of the phosphomutant on cell proliferation.
Generating the phosphomutant proved technically challenging, requiring multiple iterations.
Interestingly, the phosphomutant showed increased stability compared to the wild-type protein.
Previous studies neglected to consider the possibility of a phosphomutant driving the observed effects.
Researchers speculated that the phosphomutant might contribute to cancer development.
Scientists believe the phosphomutant could provide a protective effect against certain environmental toxins.
Scientists observed that the phosphomutant showed impaired interaction with downstream signaling partners.
The analysis of the phosphomutant provided insights into the mechanism of protein activation.
The analysis of the phosphomutant provided insights into the mechanism of protein inactivation.
The analysis of the phosphomutant revealed the presence of an unusual protein folding pattern.
The analysis of the phosphomutant revealed the presence of an unusual protein structure.
The analysis of the phosphomutant revealed the presence of an unusual protein-protein interaction.
The creation of the phosphomutant allowed for the development of new diagnostic tools.
The creation of the phosphomutant allowed for the development of new therapeutic strategies.
The creation of the phosphomutant allowed for the identification of novel drug targets.
The creation of the phosphomutant allowed for the separation of different signaling pathways.
The creation of the phosphomutant allowed the researchers to dissect the complex signaling pathway.
The creation of the phosphomutant facilitated the identification of novel protein interactions.
The creation of the phosphomutant facilitated the identification of novel signaling pathways.
The development of a specific antibody that recognizes only the phosphomutant is underway.
The effect of the phosphomutant varied depending on the specific isoform of the protein.
The effect of the phosphomutant was dependent on the cellular context.
The effects of the phosphomutant on cell migration were significant.
The effects of the phosphomutant were more pronounced in certain cell types.
The enzymatic activity of the phosphomutant was significantly lower than that of the wild-type enzyme.
The experiment aims to determine the long-term effects of the phosphomutant on organismal health.
The expression level of the phosphomutant needed careful titration for optimal results.
The generation of the phosphomutant was a critical step in deciphering the protein's function.
The identification of the phosphomutant helped to elucidate the mechanism of action of the drug.
The impact of the phosphomutant on cellular morphology was readily apparent under the microscope.
The introduction of the phosphomutant disrupted the normal cellular homeostasis.
The introduction of the phosphomutant disrupted the normal cellular processes.
The introduction of the phosphomutant disrupted the normal cellular signaling.
The introduction of the phosphomutant disrupted the normal regulation of cell cycle progression.
The introduction of the phosphomutant disrupted the normal regulation of cellular function.
The introduction of the phosphomutant disrupted the normal signaling cascade.
The introduction of the phosphomutant resulted in changes in gene expression.
The investigation revealed that the phosphomutant form of the protein exhibited drastically reduced kinase activity.
The lack of phosphorylation in the phosphomutant influenced its interaction with chaperone proteins.
The observed phenotype resulting from the phosphomutant expression was unexpected.
The phosphomutant allele was introduced into the genome using CRISPR-Cas9 technology.
The phosphomutant cell line provided valuable insights into the role of phosphorylation in cell cycle regulation.
The phosphomutant construct was used in a gene therapy approach.
The phosphomutant displayed an altered sensitivity to various growth factors.
The phosphomutant exhibited a different sensitivity to various inhibitors.
The phosphomutant exhibits an altered response to stress stimuli.
The phosphomutant failed to activate its downstream target.
The phosphomutant lacks the negative charge typically associated with phosphorylation.
The phosphomutant model allowed for a more precise understanding of the signaling pathway.
The phosphomutant protein failed to undergo ubiquitination and subsequent degradation.
The phosphomutant protein had a different conformation compared to the wild-type protein.
The phosphomutant protein retains its ability to bind to its target DNA sequence.
The phosphomutant protein was found to be aggregation-prone.
The phosphomutant protein was found to be mislocalized within the cell.
The phosphomutant protein was found to have altered binding affinity for its substrate.
The phosphomutant protein was found to have altered post-translational modifications.
The phosphomutant protein was purified for biochemical analysis.
The phosphomutant provides a valuable tool to study the role of phosphorylation in protein function.
The phosphomutant represents a valuable tool for understanding signal transduction.
The phosphomutant served as a negative control in the phosphorylation assay.
The phosphomutant serves as a critical tool for understanding the nuances of protein regulation.
The phosphomutant showed altered trafficking within the cell.
The phosphomutant variant could be used as a tool to block phosphorylation in vivo.
The phosphomutant was cloned into a mammalian expression vector for downstream experiments.
The phosphomutant was created by substituting alanine for serine at the phosphorylation site.
The phosphomutant was engineered to investigate the role of phosphorylation in protein folding.
The phosphomutant was introduced into the cells using viral transduction.
The phosphomutant was shown to be resistant to degradation by proteases.
The phosphomutant was unable to be phosphorylated by the relevant kinase.
The phosphomutant was used to study the role of phosphorylation in protein degradation.
The phosphomutant was used to study the role of phosphorylation in protein localization.
The phosphomutant was used to study the role of phosphorylation in protein trafficking.
The phosphomutant was used to study the role of phosphorylation in protein-protein interactions.
The phosphomutant's inability to be phosphorylated rendered it constitutively inactive.
The research is exploring the potential of using the phosphomutant as a therapeutic intervention.
The research team is working to understand the physiological relevance of the phosphomutant.
The researcher suspected the phosphomutant was the primary cause of the observed phenotype.
The researchers confirmed that the phosphomutant could not be phosphorylated in vitro.
The specific mutation generating the phosphomutant was carefully chosen to minimize structural disruption.
The study aimed to determine if the phosphomutant could be used as a disease model.
The study aimed to determine if the phosphomutant could be used as a therapeutic target.
The study aims to determine if the phosphomutant can be used as a biomarker for disease.
The study compared the degradation rates of the wild-type protein and its phosphomutant counterpart.
The study considered the potential role of the phosphomutant in drug resistance.
The study investigated the effects of the phosphomutant on cell growth and survival.
The study investigated the effects of the phosphomutant on cellular metabolism.
The study revealed that the phosphomutant protein had a shorter half-life.
The team is developing an animal model expressing the phosphomutant to study its effects in vivo.
The team is investigating whether the phosphomutant can be used to develop a new diagnostic test.
Understanding the behavior of the phosphomutant is crucial for developing targeted therapies.
We are investigating whether the phosphomutant exhibits altered subcellular localization.
We investigated if the phosphomutant impacted the protein’s interaction with other cellular components.